Response Genetics, Inc (RGDXQ)

OTCMKTS · Delayed Price · Currency is USD
0.0000
+0.0000 (100.00%)
At close: Jan 5, 2026
100.00%
Market Cap 78.00
Revenue (ttm) 16.62M
Net Income (ttm) -14.21M
Shares Out 38.80M
EPS (ttm) -0.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,300
Average Volume 7,763
Open 0.0000
Previous Close 0.0000
Day's Range 0.0000 - 0.0000
52-Week Range 0.0000 - 0.0001
Beta 5.20
RSI 39.36
Earnings Date n/a

About Response Genetics

Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, Respo... [Read more]

Sector Healthcare
Founded 1999
Employees 100
Stock Exchange OTCMKTS
Ticker Symbol RGDXQ
Full Company Profile

Financial Performance

In 2014, Response Genetics's revenue was $16.72 million, a decrease of -15.56% compared to the previous year's $19.80 million. Losses were -$13.70 million, 70.8% more than in 2013.

Financial Statements

News

There is no news available yet.